使用α受体阻滞剂的男性发生髋部骨折的风险：一项基于索赔登记处的全国性研究
Risk of hip fractures in men with alpha-blockers: a nationwide study base on claim registry.
作者信息
Seo Gi-Hyeon, Lee Young-Kyun, Ha Yong-Chan
机构信息
Health Insurance Review and Assessment Service, Seoul, Korea.
Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
出版信息
J Bone Metab. 2015 Feb;22(1):29-32. doi: 10.11005/jbm.2015.22.1.29. Epub 2015 Feb 28.
BACKGROUND
Alpha-blocker can result in falling and fractures because of adverse effect such as orthostatic hypotension due to vasodilatory effect. We investigated the association between the alpha-blocker and the risk of osteoporotic hip fractures using a nationwide claim database.
METHODS
We identified 1,051,651 men 65 years of age or older who had prescription records of alpha-blocker from nationwide medical claim database, from 2007 to 2012. Alpha-blockers were classified as non-specific general (NSG), non-specific slow-release (NSSR), uro-specific general (USG), and uro-specific slow release (USSR).
RESULTS
Total of 6,553 hip fractures were observed. The incidences of hip fracture within 1 year were higher than those of the reference periods in all type of alpha-blocker. Hazard ratio peaked at early period of alpha-blocker, and decreased with time, regardless of type of alpha-blocker.
CONCLUSIONS
Use of alpha-blocker is associated with increased risk of hip fracture, especially in early use.
背景
α受体阻滞剂可因血管舒张作用导致体位性低血压等不良反应，从而引发跌倒和骨折。我们使用全国性索赔数据库研究了α受体阻滞剂与骨质疏松性髋部骨折风险之间的关联。
方法
我们从2007年至2012年的全国医疗索赔数据库中，识别出1,051,651名65岁及以上有α受体阻滞剂处方记录的男性。α受体阻滞剂分为非特异性普通型（NSG）、非特异性缓释型（NSSR）、尿路特异性普通型（USG）和尿路特异性缓释型（USSR）。
结果
共观察到6,553例髋部骨折。所有类型的α受体阻滞剂在1年内的髋部骨折发生率均高于参考期。无论α受体阻滞剂的类型如何，风险比在α受体阻滞剂使用早期达到峰值，并随时间下降。
结论
使用α受体阻滞剂与髋部骨折风险增加有关，尤其是在早期使用时。
Zotero 插件